Repetition of Serotonin Syndrome after Reexposure to SSRI

We describe here the occurrence of a serotonin syndrome (SS) in a 64-year-old depressed female patient with alcoholic hepatic cirrhosis after treatment with SSRIs. Two weeks after the increase of the dosage of sertraline, the patient developed a full-blown SS, which resolved completely after the discontinuation of the drug. The therapy with citalopram led again to development of milder SS, this time immediately after the increase of the dosage. Our case illustrates the variability of the clinical presentation and the temporal evolution of SS in a patient with preexisting medical illness affecting hepatic metabolism. Reexposure of patients with a history of SS to another serotoninergic drug should be avoided; if necessary, it must be carried out with the utmost caution.

References

• 1 Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetin associated hepatotoxicity: a report of 3 cases and a review of the literature.  Pharmacopsychiatry. 2002;  35 112-115
• 2 Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.  Clin Pharmacokinet. 1996;  31 444-469
• 3 Bottlender R, Jäger M, Hofschuster E, Dobmeier P, Möller H -J. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.  Pharmacopsychiatry. 2002;  35 119-121
• 4 Brown T M, Skop B P, Mareth T R. Pathophysiology and management of the serotonin syndrome.  Ann Pharmacother. 1996;  30 527-533
• 5 Démolis J -L, Angebaud P, Grangé J -D, Coates P, Funck-Brentano C, Jaillon P. Influence of liver cirrhosis on sertraline pharmacokinetics.  Br J Clin Pharmacol. 1996;  42 394-397
• 6 Dursun S M, Burke J G, Reveley M A. Toxic serotonin syndrome or extrapyramidal side-effects.  Br J Psychiatry. 1995;  166 401-402
• 7 Hegerl U, Bottlender R, Gallinat J, Kuss H J, Ackenheil M, Möller H J. The serotonin syndrome scale: first results on validity.  Eur Arch Psychiatry Clin Neurosci. 1998;  248 96-103
• 8 Kaneda Y, Ohmori T, Fujii A. The serotonin syndrome: investigation using the Japanese version of the Serotonin Syndrome Scale.  Psychiatry Res. 2001;  105 135-142
• 9 Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb W H, Eckl K M, Dierdorf H -D, Wolf D. The pharmacokinetics of paroxetine in patients with liver cirrhosis.  Acta Psychiatr Scand. 1989;  80 (suppl 350) 91-92
• 10 Kudo K, Sasaki I, Tsuchiyama K, Akiyoshi J, Nagayama H, Fujii I. Serotonin syndrome during clomipramine monotherapy: comparison of two diagnostic criteria.  Psychiatry Clin Neurosci. 1997;  51 43-46
• 11 Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.  J Clin Psychopharmacol. 1997;  17 208-221
• 12 Lejoyeux M, Adès J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment.  CNS Drugs. 1994;  2 132-143
• 13 Lejoyeux M, Rouillon F, Adès J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine.  Acta Psychiatr Scand. 1993;  88 369-371
• 14 Mills K C. Serotonin syndrome.  Am Fam Physician. 1995;  52 1475-1482
• 15 Radomski J W, Dursun S M, Reveley M A. Toxic serotonin syndrome (TTS): an update and revised diagnostic criteria (abstract).  J Psychopharmacol. 1995;  9 (suppl 2) A21
• 16 Sternbach H. The serotonin syndrome.  Am J Psychiatry. 1991;  148 705-713